Detailed Narrative
Strategic Review and Cost Optimization
Viatris completed an enterprise-wide strategic review, identifying $650 million in gross cost savings over three years, with $250 million planned for reinvestment. These savings are expected to be evenly split between SG&A and COGS, phased over 2026-2028, aiming to strengthen competitiveness and support sustainable growth. The review focused on modernizing the organization post-divestitures and optimizing infrastructure, with approximately 50% of savings from headcount reductions and the remainder from COGS efficiencies, inventory management, and support structures.
Pipeline and Regulatory Milestones
The company anticipates 8 regulatory approvals for 6 product candidates in 2026, including Effexor and pitolisant in Japan, phentolamine ophthalmic solution, low-dose estrogen weekly patch, and fast-acting meloxicam in the U.S., and sotagliflozin in Australia and Canada. Key Phase III programs like cenerimod and selatogrel are nearing full enrollment, with readouts expected in late 2026 or early 2027. The generic pipeline and established brand portfolio are expected to account for over 100 new product approvals globally in 2026.
Japan Market Focus and Strategy
Japan is a critical market, historically facing downward pressure from mandatory annual price decreases and structural challenges. Viatris is strategically adding assets like Effexor GAD, pitolisant, and Spydia to transition the region from revenue and EBITDA decline to growth by 2028 and beyond. The mid-year Amitiza LOE in Japan is noted as a headwind for 2026, but the company is confident in the long-term trajectory with new product launches.
Fast-Acting Meloxicam Launch Strategy
With an NDA submission imminent following a positive pre-NDA meeting with the FDA, fast-acting meloxicam is poised to address the acute pain market, particularly post-operative and operative pain. The company plans a specialty sales force targeting surgeons, orthopedic surgeons, and dental surgeons, with potential partnerships to expand reach beyond these initial targets. The product is expected to be a long-term contributor, potentially into the 2030s, due to exclusivity and intellectual property protection, with opioid-sparing language anticipated in the label.
Capital Allocation and Financial Flexibility
Viatris expects robust cash flow in 2026, providing over $2.5 billion for deployment, including excess cash on hand and net proceeds from the Biocon monetization. Priorities include accretive in-market business development, continued shareholder returns (dividends), and debt paydown to achieve a gross leverage range of 2.8x to 3.2x. The company is not focused on acquiring early-stage pipeline assets but rather commercial-stage assets that can drive near-term growth.
2026 Outlook and Phasing
The company expects 2026 to be a stabilization year, with total revenues and adjusted EBITDA growing approximately 2%. New product revenues are projected at $450 million to $550 million. The second half of 2026 is expected to be stronger for revenues, adjusted EBITDA, and adjusted EPS due to product seasonality and launch timing, while Q1 will be the lowest for revenues, gross margins, and free cash flow, impacted by working capital, one-time📎 operating cash costs, and transaction/restructuring costs.